Supplementary Table 1 Methods of biomarker measurement, material, dilution and units

Biomarker	Manufacturer	Reference	Dilution	LLOQ	Units
ApoCIII	Abnova	KA0465	1/2500	0.002	µg/mL
D-Dimer	Stago	947	1/42	10	ng/mL
Endostatin	R&D	RYD-DNST0	1/50	0.023	ng/mL
GroA	Aushon 3-plex	85,723	1/2	0.39	pg/mL
IL6	Aushon 3-plex	85,723	1/2	0.20	pg/mL
NTPROBNP	Roche	4,842,464	1/1	5	pg/mL
VAP1	eBioscience	BMS259TEN	1/1000	0.019	ng/mL
VWF	Stago	942	1/102	1	%

LLOQ: lower limit of quantification; ApoCIII: apolipoprotein CIII; GroA: growth-related oncogen alpha; IL-6: interleukin-6; NTproBNP: N-terminal pro B-type natriuretic peptide; VAP-1: vascular adhesion protein-1; vWF: Von Willebrand factor.

Supplementary Table 2 Results of the binary logistic regression analysis that evaluated the diagnostic value of clinical variables.

Variable	Clinical Model		
Logistic Regression			
	OR	[95% CI]	p value
Sex	0.585	(0.30;1.10)	0.103
Age	1.032	(1.00;1.05)	0.011[+]
Hypertension	1.059	(1.47;2.35)	0.886
Dyslipidemia	1.618	(0.83;3.16)	0.156
NIHSS at admission	1.368	(1.12;1.72)	0.003[+]
ROC curve	AUC	[95% CI]	
	0.72	(0.65;0.79)	

The table shows the results of the clinical model as well as the odd ratios, the confidence interval and the p value for variables. *LRT indicates likelihood- ratio test *AUC indicates area under the curve. [+]P value <0.05.

Supplementary Figure 1. Correlation between clinical variables (age, tas) and biomarkers. ApoCIII: apolipoprotein CIII; GroA: growth-related oncogen alpha; IL-6: interleukin-6; NTproBNP: N-terminal pro B-type natriuretic peptide; VAP-1: vascular adhesion protein-1; vWF: Von Willebrand factor. Tas: Blood pressure.